These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19484628)

  • 1. A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught?
    Tenovuo O; Alin J; Helenius H
    Brain Inj; 2009 Jun; 23(6):548-58. PubMed ID: 19484628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
    Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
    Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of rivastigmine capsules in patients with traumatic brain injury.
    Silver JM; Koumaras B; Meng X; Potkin SG; Reyes PF; Harvey PD; Katz DI; Gunay I; Arciniegas DB
    Brain Inj; 2009 Feb; 23(2):123-32. PubMed ID: 19191091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
    Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
    Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
    Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R
    BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
    Almaraz AC; Driver-Dunckley ED; Woodruff BK; Wellik KE; Caselli RJ; Demaerschalk BM; Adler CH; Caviness JN; Wingerchuk DM
    Neurologist; 2009 Jul; 15(4):234-7. PubMed ID: 19590387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
    van Eijk MM; Roes KC; Honing ML; Kuiper MA; Karakus A; van der Jagt M; Spronk PE; van Gool WA; van der Mast RC; Kesecioglu J; Slooter AJ
    Lancet; 2010 Nov; 376(9755):1829-37. PubMed ID: 21056464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.
    Tenovuo O
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):61-7. PubMed ID: 15610946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients.
    Mäurer M; Ortler S; Baier M; Meergans M; Scherer P; Hofmann W; Tracik F
    Mult Scler; 2013 Apr; 19(5):631-8. PubMed ID: 23069874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
    Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
    Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
    Brawman-Mintzer O; Tang XC; Bizien M; Harvey PD; Horner MD; Arciniegas DB; Raskind M; Johnson-Greene L; Martineau RJ; Hamner M; Rodriguez-Suarez M; Jorge RE; McGarity S; Wortzel HS; Wei Y; Sindowski T; Mintzer J; Kindy AZ; Donovan K; Reda D
    J Neurotrauma; 2021 Jul; 38(14):1943-1952. PubMed ID: 33514274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.